IL5 and asthma: Recently, Soendergaard et al., in the OPTIMAL study, suggested that gradual down-titration of anti-IL-5 biologics in severe asthma could be a more appropriate approach to evaluate whether a reduction in or cessation of treatment could be possible, raising concerns for personalized dosing intervals in the future [25].